| Identification | Back Directory | [Name]
MDL 72527 | [CAS]
93565-01-6 | [Synonyms]
CPC-200
MDL727527
MDL 72527
Mdl-72527da
MDL 72527, >=97%
MDL-72527
(MDL72527
MDL 72527 (hydrochloride)
N1,N4-Bis(2,3-butadienyl)putrescine
N,N'-Bis(2,3-butadienyl)-1,4-butanediamine
N1,N4-Di(buta-2,3-dienyl)butane-1,4-diamine
N,N'-Bis(2,3-butanedienyl)-1,4-butanediamine
N,N'-di(buta-2,3-dien-1-yl)butane-1,4-diaMine
N1,N4-Di-2,3-butadienyl-1,4-butanediaminedihydrochloride
N1,N4-bis(2,3-Butadienyl)-1,4-butanediamine hydrochloride
N,N'-bis(2,3-Butadienyl)-1,4-butanediamine dihydrochloride
N1,N4-DI(BUTA-2,3-DIENYL)BUTANE-1,4-DIAMINE DIHYDROCHLORIDE
N1,N4-Di(buta-2,3-dien-1-yl)butane-1,4-diaMine dihydrochloride | [Molecular Formula]
C12H20N2.2HCl | [MDL Number]
MFCD13152261 | [MOL File]
93565-01-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
236-237 °C (decomp)(Solv: ethanol (64-17-5); ethyl acetate (141-78-6)) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
H2O: soluble15mg/mL, clear | [form ]
powder | [color ]
light yellow to light brown | [Water Solubility ]
H2O: 15mg/mL, clear | [InChI]
1S/C12H20N2.2ClH/c1-3-5-9-13-11-7-8-12-14-10-6-4-2;;/h5-6,13-14H,1-2,7-12H2;2*1H | [InChIKey]
ITVRWVVFVHINOH-UHFFFAOYSA-N | [SMILES]
Cl.Cl.C=C=CCNCCCCNCC=C=C |
| Hazard Information | Back Directory | [Uses]
MDL 72527 is a lysosomotropic polyamineoxidase inhibitor. | [Biological Activity]
Polyamine oxidase (POA) inhibitor. Does not inhibit monoamine oxidase or D-Amino acid oxidase. Displays anticancer and neuroprotective activity in vivo . | [in vivo]
MDL 72527 (100 mg/kg; i.p.; once) shows neuroprotective against neuronal cell damage after temporary focal cerebral ischemia[1]. | Animal Model: | 250-300 g, Male spontaneously hypertensive rats (SHRs)[1] | | Dosage: | 100 mg/kg | | Administration: | I.p.; after the induction of ischemia | | Result: | Significantly reduced meanarterial blood pressure, changed the brain edema formation from 85.7 ± 0.3 to 84.5 ± 0.9% in cortex and from 79.9 ± 1.7 to 78.4 ± 2.0% in subcortex (difference not significant), reduced ischemic injury volume by 22% in the cortex and 17% in the subcortex. |
|
|
|